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Abstract
Background: Acute painful swelling of the extremities and scrotum are debilitating clinical manifestations of Wuchereria
bancrofti infection. The ongoing global program to eliminate filariasis using mass drug administration is expected to
decrease this and other forms of filarial morbidity in the future by preventing establishment of new infections as a
consequence of eliminating transmission by the mosquito vector. We examined whether mass treatment with anti-filarial
drugs has a more immediate health benefit by monitoring acute filariasis morbidity in Papua New Guinean communities
that participated in a 5-year mass drug administration trial.
Methodology/Principal Findings: Weekly active surveillance for acute filariasis morbidity defined by painful swelling of the
extremities, scrotum and breast was performed 1 year before and each year after 4 annual mass administrations of anti-
filarial drugs (16,480 person-years of observation). Acute morbidity events lasted ,3 weeks in 92% of affected individuals
and primarily involved the leg (74–79% of all annual events). The incidence for all communities considered together
decreased from 0.39 per person-year in the pre-treatment year to 0.31, 0.15, 0.19 and 0.20 after each of 4 annual treatments
(p,0.0001). Residents of communities with high pre-treatment transmission intensities (224–742 infective bites/person/
year) experienced a greater reduction in acute morbidity (0.62 episodes per person-year pre-treatment vs. 0.30 in the 4
th
post-treatment year) than residents of communities with moderate pre-treatment transmission intensities (24–167 infective
bites/person/year; 0.28 episodes per person-year pre-treatment vs. 0.16 in the 4
th post-treatment year).
Conclusions: Mass administration of anti-filarial drugs results in immediate health benefit by decreasing the incidence of
acute attacks of leg and arm swelling in people with pre-existing infection. Reduction in acute filariasis morbidity parallels
decreased transmission intensity, suggesting that continuing exposure to infective mosquitoes is involved in the
pathogenesis of acute filariasis morbidity.
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Introduction
The goals of the ongoing global effort to eliminate lymphatic
filariasis (LF) are to promote mass administration of anti-filarial
drugs (MDA) in order to reduce and ultimately stop mosquito-
borne transmission of Wuchereria bancrofti and to alleviate physical
disability, suffering and economic disempowerment due to the
pathology associated with this parasitic worm infection (www.
filariasis.org). Increasing evidence supports the feasibility of
achieving the first goal in circumstances where the public health
infrastructure is capable of delivering MDA over a sufficient
period of time and at the level of population coverage that is
necessary to stop transmission. For example, in Egypt where pre-
MDA microfilaria-positive infection rates were ,5%, a national
program consisting of annual treatment with diethylcarbamazine
plus albendazole led to nearly complete elimination of microfilar-
ia-positive carriers in the target population and possibly cessation
of transmission when annual MDA was sustained for 5 years with
population coverage .80% [1]. Results of MDA trials in areas
where human and mosquito infection rates are higher than in
Egypt also suggest that MDA may reduce the reservoir of
microfilaria carriers sufficiently to prevent the establishment of
new infections in children [2,3]. By contrast, data pertinent to the
impact of MDA on LF morbidity are more limited.
Developing, implementing and sustaining a public health
program to treat and prevent LF morbidity are formidable tasks.
Education in the use of footwear and attention to foot and leg
hygiene aimed at reducing secondary bacterial infections of the
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lymphedema and acute swelling of the leg [4–9]. However, the
overall impact of this strategy, with or without coincidental MDA,
has not been evaluated systematically for effectiveness or
sustainability at the population level. This gap in knowledge is
not surprising given the small proportion of LF-exposed
individuals who experience clinically overt LF morbidity (usually
,5% of infected individuals) and the logistical challenge of
prospectively evaluating the three main forms of LF morbidity –
chronic lymphedema of the extremities (e.g., elephantiasis),
disfigurement of the scrotum (e.g., hydrocele) and acute filariasis
morbidity characterized by transient painful swelling of the
extremities (especially the leg) and, less commonly, the scrotum.
Fever with acute swelling and pain of an extremity or other
anatomical locations such as the scrotum, here collectively referred
to as acute filariasis morbidity (AFM), have been highlighted in the
global elimination program as among the most common
manifestations of LF morbidity that adversely affects individual
and population health, particularly in communities where physical
labor is important for economic well-being [10–12]. The
pathogenesis of AFM is poorly understood, and is likely to have
several etiologies that include the direct effects of filarial mediators
on lymphatic function, immune-mediated inflammatory reactions
to various stages of the W. bancrofti life cycle, innate immune
responses to Wolbachia endosymbionts and secondary bacterial
infections of the skin associated with pre-existing lymphatic
dysfunction [8,12–16]. Earlier studies have referred to acute
painful swelling of the limbs in LF-infected individuals as acute
filarial lymphangitis, posited to be due to inflammatory reaction
elicited by dying lymphatic dwelling adult worms and/or allergic
responses to third- or fourth-stage filarial larvae. A related
syndrome with a prominent dermal component, referred to as
acute dermatolymphangioadenitis, also occurs and is posited to be
due to secondary bacterial infection of the skin [8–11]. These and
other reports of AFM have focused primarily on the clinical
management of self-referred patients. For example, prophylaxis
with anti-filarial drugs and antibiotics given to patients in India
who presented to local health facilities with fever and limb swelling
decreased the rate of recurrence to one-sixth the pre-treatment
rate [17–19]. On the other hand, prospective community-based
studies of AFM are less commonly conducted and difficult to
perform because the phenotype is transient (lasting from a few
days to 1–3 weeks), unpredictable in the time of appearance, and
confirmatory laboratory tests or biomarkers are non-existent.
Previous attempts to identify risk factors for AFM have been
limited to 1 year of observation in situations where MDA has not
been implemented. These reports describe variability in the
incidence of AFM according to endemic region, ranging from 0.03
episodes per person-year in Tanzania [20], 0.10 episodes per
person-year in India [21] and Ghana [22], and 0.31 episodes per
person-year in Papua New Guinea [23]. Increasing age and pre-
existing chronic lymphatic pathology such as lymphedema of the
leg were significant risk factors.
We report here the results of 5 years of weekly active
surveillance for AFM in a population who participated in a
community-randomized MDA trial conducted in Papua New
Guinea from 1993 to 1998 [3,23,24]. The major objective of
the trial was to compare the efficacy of single annual dose
diethylcarbamazine alone to diethylcarbamazine combined with
ivermectin in reducing transmission of W. bancrofti by the local
mosquito vectors Anopheles punctulatus and An. koliensis. The two
MDA regimens were observed to have similar efficacy in reducing
LF transmission by the end of the 5-year surveillance period.
Because this trial was conducted prior to current recommenda-
tions by the World Health Organization that educational
programs to maintain skin and extremity hygiene be integrated
into LF elimination programs [8,9,25,26], we were able to
determine whether MDA by itself affects the incidence and
severity of AFM.
Methods
Ethics Statement
The Medical Research Advisory Committee of the Papua New
Guinea Department of Health and the University Hospitals of
Cleveland/Case Western Reserve University Institutional Review
Board for Human Studies reviewed and approved conduct of the
study. Written informed consent was obtained from participants
older than 18 years and parents or guardians of persons whose age
was 5 to 17 years. Children younger than 5 years and women who
were pregnant at the time of the annual drug administration were
not eligible to take anti-filarial drugs.
Objectives
The objective was to determine whether the incidence of AFM
was affected by annual mass administration of anti-filarial drugs
that reduce the microfilaria reservoir and thereby decrease
transmission of W. bancrofti infective third-stage larvae by local
mosquito vectors. We tested the hypothesis that reduced mosquito
transmission of W. bancrofti mediated by mass drug administration
decreases acute filariasis morbidity as a consequence of diminished
exposure to infective third- or fourth- stage larvae in the absence of
curing pre-existing infection.
Participants
All data were collected as part of a community randomized trial
to test the efficacy of MDA with single annual dose diethylcar-
bamazine alone versus diethylcarbamazine plus ivermectin to
reduce mosquito-borne transmission of W. bancrofti. The study was
performed from 1993 to 1998 in the Dreikikir district of East Sepik
Province, Papua New Guinea [3,23,27]. The observation period
for AFM began 1 year before the first annual MDA and continued
for each year after four annual MDAs.
Author Summary
The global program to eliminate lymphatic filariasis
recommends 5 or more annual rounds of mass anti-filarial
drug administration in order to reduce the reservoir of
microfilaria to a level that will not sustain continuing
transmission of infection by mosquitoes. We examined the
incidence of acute filariasis morbidity defined by self-
reported episodes of acute painful swelling of the
extremities or scrotum in residents of communities in
Papua New Guinea who participated in a 5-year mass drug
administration trial. Acute morbidity events primarily
affected the legs and arms, lasted less than 3 weeks,
increased transiently following the first annual mass drug
administration, and decreased progressively after repeated
annual treatments. Risk factors for acute morbidity
included pre-treatment microfilaremia and filarial antigen-
emia, pre-existing lymphatic pathology of the legs
documented by physical examination, age older than 45
years and residence in communities where pre-treatment
transmission intensity was relatively high. Results of our
study indicate that mass administration of anti-filarial
drugs has immediate clinical benefit to endemic commu-
nities in addition to future transmission cessation.
Acute Filariasis Morbidity in Papua New Guinea
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Prospective weekly monitoring for AFM. Field reporters
recruited from local residents and trained by the research team
performed weekly active surveillance in study villages by
questioning each resident. The questionnaires asked whether a
participant experienced swelling of the leg, arm, scrotum, or breast
with or without fever on the day of the reporter’s visit, during the
preceding 1 or 2 days or during the previous week. Responses to
questionswere recorded onstandardizedprintedmorbidityformsin
the local dialect. Data from the forms were entered into a database
and linked with demography, census data, weekly migration records
and records of anti-filarial drug administration, as described
previously [23]. Demographic information such as age, sex and
household of residence was updated monthly. AFM was defined as
self-reported swelling of the leg, arm, scrotum or breast with the
presence of fever during the previous week [23]. The duration of
AFM was calculated such that a single event was defined by at least
2 weeks of negative questionnaire answers that preceded and
followed 1 or more weeks of positive answers for AFM. Annual
follow-up observations were standardized to the date of drug
administration for each individual since study periods varied
between annual MDA administrations for logistical reasons
(intervals between consecutive annual MDAs ranged from 361 to
403 days per study year). The study population varied between
3,385 and 3,591 individuals for each year of observation. Person-
time was calculated according to eligible weeks of observation for
each individual. Time spent outside the study area and village of
residence(e.g.dueto migration)andprevalentdisease time werenot
included in the observation time.
Annual determination of infection status and chronic LF
pathology. Annual physical examination for signs of chronic LF
morbidity such as lymphedema of an extremity and hydrocele
were performed by JWK and other clinicians according to
recommendations from the World Health Organization [28].
Yearly blood samples were obtained the night before
administration of anti-filarial drugs in order to determine
microfilaremia by the NucleporeH filtration method. Og4C3
circulating filarial antigen levels were measured in samples
obtained the day before the first MDA and 1 year after the
fourth MDA. Filarial antigenemia was scored as negative, low or
high as described previously [3,24].
Entomological monitoring. Mosquitoes were captured by
the landing catch method and results expressed as the annual
infective biting rate, i.e. the number of blood-seeking mosquitoes
containing at least 1 W. bancrofti infective larva that a person would
be exposed to over a 1-year period [3,24,29].
Statistical methods
Chi square tests were used to test differences in proportions. T-
tests were used to compare differences in frequencies. Poisson
regression (using the GENMOD procedure) was used to estimate
the incident rate ratios (IRR) and 95% confidence intervals (CI) of
AFM while incorporating multiple records of the same person in
different years. Overdispersion was assessed using Pearson
residuals. Negative binomial models were used to obtain standard
error estimates when overdispersion was detected. Incidence ratios
were calculated for baseline transmission intensity, age, sex,
chronic disease status, microfilaremia status and density, and
filarial antigenemia. Temporal effects of MDAs were evaluated by
stratification and by including a variable for study year, controlling
for repeated measures among individuals. In addition, stratified
models were used to evaluate treatment-related effects after each
MDA according to rapid (4 weeks immediately following MDA)
and long-term (remaining 48 weeks of the study year) follow-up
after MDA. Quasi-likelihood ratio tests were performed to
compare models and select predictors for AFM incidence (i.e.
age, sex, chronic LF pathology, presence or absence of
microfilaremia, and filarial antigenemia). Model assumptions were
evaluated by calculating deviance from the full model and
autocorrelation plots of residuals. All analyses were performed
with SAS version 9.1 (Carey, North Carolina, USA).
Limitations
Observations in this study were made at a time (1993 to 1998)
before the current World Health Organization recommendation
for mass drug administration to eliminate lymphatic filariasis
outside Africa be annual diethylcarbamazine combined with
albendazole. We used diethylcarbamazine alone and diethylcar-
bamazine combined with ivermectin in our randomized commu-
nity trial. These drugs were under consideration for mass drug
administration at the time the study was performed. We do not
believe that the use of these anti-filarial drugs diminishes the
significance of the findings related to acute filariasis morbidity and
MDA since: a) Mosquito transmission was effectively reduced in
our earlier trial; b) There was no difference in the magnitude of
transmission reduction effected by the diethylcarbamazine alone
versus diethylcarbamazine combined with ivermectin; and, c) The
anti-filarial drug with the highest activity against microfilaria and
adult worms is diethylcarbamazine. Additional limitations relate to
the fact that acute filariasis morbidity events that we tracked were
self-reported and not documented by repeated physical examina-
tion or imaging studies of lymphatic vessels or lymph nodes.
Results
Morbidity surveillance was performed on an open cohort during
a 5-year annual MDA field trial, including 1 year of observation
before the first annual round of MDA. Self-reported disease events
and physical examinations for lymphedema of an extremity and
hydrocele were observed for a total of 16,480 person-years. The
absolute number of AFM events ranged from 1,445 during the
pre-MDA year to 514 events during the year following 2 annual
MDAs, corresponding respectively to incidences of 0.39 and 0.15
per person-year of observation (Table 1). The duration of AFM
events was similar throughout the 5-year observation period, with
92% of events lasting 1 to #3 weeks as previously described in this
study population [23]. Only 0.3% of events were recording as
having a duration .10 weeks. AFM events were estimated for all
potential disease locations: leg, arm, scrotum and breast. Leg
events accounted for 76% of the total 4,149 AFM events (range of
the 5 annual values 74–79%, Table 1). Events involving the arm
occurred in 10% of the participants. All other locations accounted
for ,10% of AFM events, and occurred at rates of ,0.02 per
person-year of observation.
Incidence of AFM according to timing of MDA
AFM incidence decreased from 0.39 per person-year of
observation in the pre-treatment year to 0.31, 0.15, 0.19 and
0.20 after each of 4 consecutive MDAs (p,0.0001). The
reductions in AFM rate following the first MDA according to
disease location were 19%, 16%, 4% and 45% for leg, arm,
scrotum and breast, respectively. The reductions in AFM rate
following the second MDA were 58%, 67%, 60% and 77% of pre-
MDA rates for leg, arm, scrotum and breast. Although the
frequency of AFM decreased during the 5-year study period, the
anatomical distribution of AFM events remained stable, with legs
accounting for 74% of all events. AFM affecting the arm, scrotum
and breast constituted the remaining 12%, 9% and 5%.
Acute Filariasis Morbidity in Papua New Guinea
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decreased by 20% during the year following the first MDA and by
49–61% in subsequent years relative to pre-MDA rates (Table 1).
In order to assess whether treatment-related acute events were
putatively caused by rapid killing of microfilaria by anti-filarial
drugs [30], AFM was evaluated separately during the first 4-week
period after each MDA. The incidence during the 4-week period
immediately following the first MDA was significantly higher than
the remaining 48 weeks of the same year (0.73 versus 0.28 per
person-year of observation, p,0.001) (Figure 1), and was the only
time period during which weekly AFM events were more frequent
than the pre-MDA year (227%, 115%, 73% and 10% increases
over pre-MDA incidence for arm, scrotum, leg and breast,
respectively). This large transient increase in AFM was not
observed following subsequent MDAs (Figures 1 and 2) although a
smaller increase did achieve statistical significance in study year 4
(0.26 per person-year of observation in the first four weeks after
MDA versus 0.19 in the remaining 48 weeks of the same year,
p=0.023) (Figure 1).
Microfilaremia as a risk factor for AFM
Microfilaremia was associated with the abrupt increase in AFM
incidence during the 4-week period immediately following the first
MDA; 8.3% of microfilaria-positive individuals experienced at
least one episode of AFM versus 5.6% of microfilaria-negative
individuals (p=0.013). This corresponds to 35% greater risk for
microfilaria-positive versus microfilaria-negative individuals dur-
ing the month following the first MDA (95% CI=1.14–1.61,
p,0.0006). When the four week post-MDA period was excluded
from the analysis of the study year, AFM incidence did not vary
significantly according to microfilaremia. Furthermore, AFM rates
did not differ according to microfilaremic status or density
(categorized as 0, 1–9, 10–99 and $100 microfilaria per ml)
during any other study periods.
Transmission intensity and AFM
Study communities were stratified according to whether the pre-
MDA transmission potential was moderate or high (24–167 versus
224–742 infective bites/person/year) [24]. AFM incidence during
the pre-treatment year was significantly higher in the high-
transmission communities (0.62 per person-year of observation,
95% CI=0.58–0.67) than the moderate-transmission communi-
ties (0.28 per person-year of observation, 95% CI=0.26–0.30,
Table 2). AFM incidence after the second annual MDA was
reduced by 57% relative to pre-MDA in areas of moderate
transmission and by 61% in areas of high transmission,
corresponding to a 97% and 84% reduction in transmission
potential, respectively [24]. In the year after the fourth MDA the
incidence was reduced by 43% in moderate-transmission com-
munities and by 52% in high-transmission communities. The
decreased frequency of AFM corresponded with a drop in annual
infective biting rate to near zero in moderate-transmission
communities and to 23–234 infective bites/person/year in the
high-transmission communities 1 year after the fourth MDA [3].
The incidence of AFM in the high-transmission communities
during the year after the fourth MDA (0.30 and 0.24 per person-
year of observation for all anatomic sites combined and the leg
only) was similar to the incidence of AFM among residents of
moderate-transmission communities during the pre-MDA year.
Accordingly, residents of high-transmission communities still
experienced twice the risk of AFM compared to residents of
moderate-transmission communities after 4 annual MDAs
(Table 2, Figure 3).
Filarial antigenemia and its association with AFM
Filarial antigenemia was measured using plasma obtained 1 day
before the first MDA (pre-MDA value) and 4 years later (1 year
after the fourth MDA). The antigen-positive prevalence at these
two time points (72% and 67%, respectively) did not significantly
differ despite the intervening administration of four annual MDAs.
Individuals who were filarial antigen-positive before MDA began
were more likely to experience AFM than those who were antigen-
negative (IRR=1.47, 95% CI=1.30–1.66, p,0.0001). Further,
individuals with high filarial antigenemia were more likely to
experience AFM events than those with low antigenemia (30%
versus 16%, p,0.0001) or with negative antigen status (30%
versus 14%, p,0.0001). 14% of individuals who were microfilaria-
negative and antigen-negative (i.e. no detectable LF infection)
during the pre-treatment year experienced events that were
classified as AFM. During the final year of observation (following
the fourth annual MDAs) 10% of individuals who were
microfilaria-negative and antigen-negative (i.e. no detectable LF
infection) experienced events that were classified as AFM. AFM
events among those people without detectable infection (by
antigen and microfilaremia in the first year and by microfilaremia
only in subsequent years) corresponded to 6.7% of the total events
observed over the 5 years of observation.
Multivariable models
Multivariable models were used to evaluate independent risk
factors for AFM. The variables included age (, versus $45 years),
pre-treatment community transmission intensity (expressed as the
Table 1. Population characteristics and acute filariasis morbidity events according to study year.
Study Year 1 Study Year 2 Study Year 3 Study Year 4 Study Year 5
Pre-treatment
Year
Year Following
1st MDA
*
Year Following
2nd MDA
Year Following
3rd MDA
Year Following
4th MDA
Population (n) 3,385 3,390 3,382 3,437 3,591
Person-years of observation 3,742 3,050 3,336 3,104 3,248
Total number of acute events 1,445 944 514 601 645
Total number of leg episodes 1,075 710 404 446 498
All events/pyo{ 0.39 0.31 0.15 0.19 0.20
Leg events only/pyo 0.29 0.23 0.12 0.14 0.15
*Mass drug administration (MDA) was conducted in Study Year 5 given but surveillance in the following year was not undertaken.
{pyo=person-years of observation.
doi:10.1371/journal.pntd.0001241.t001
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ma and hydrocele (documented during annual physical examina-
tion), microfilaremia, year of study, and the number of anti-filarial
drug treatments actually taken (drug administration was directly
observed). Filarial Og4C3 antigenemia was only included in
models restricted to years in which this variable was measured
(pre-MDA year and at the very end of year 5). With regard to the
complete 5-year study period, individuals experienced the greatest
risk of AFM in association with chronic leg lymphedema with a
duration $1 year (IRR=8.89, 95% CI=7.00–11.30, p,0.0001;
Table S1). Age and residence in a high-transmission community
were also significant predictors of AFM (IRR=2.20, 95%
Figure 1. Incidence of acute filariasis morbidity during 5-year mass drug administration trial. Vertical bars around each value are 95%
Confidence Intervals (CI). MDA=Mass Drug Administration (combined data from communities given diethylcarbamazine alone or diethylcarbamazine
with ivermectin), AFM=acute filariasis morbidity, person-years of observation=pyo.
doi:10.1371/journal.pntd.0001241.g001
Figure 2. Weekly frequency of acute filariasis morbidity events during the 5-year observation period. Mass drug administration (MDA)
was provided annually (i.e., at 52, 104, 156, 208 standardized weeks). The only peak of acute filariasis morbidity (AFM) occurred in the 4 weeks
following the first MDA.
doi:10.1371/journal.pntd.0001241.g002
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p,0.0001, respectively). Individuals who did not receive any
MDA (e.g. refused, absent during the period of annual MDA),
were at significantly greater risk for AFM than those who received
2 to 4 annual doses of anti-filarial drugs (IRR=3.07, 95%
CI=2.25–4.20, p,0.0001). There was no significant difference in
the risk of AFM related to drug regimen (diethylcarbamazine or
diethylcarbamazine combined with ivermectin). Microfilaremia
was included in preliminary models but dropped from final models
due to the absence of observable effect.
Additional models were analyzed for individual study years with
a focus on the pre-MDA year and the last year of observation
following the fourth MDA (when Og4C3 antigen data were
available). Microfilaremia was an independent predictor of AFM
only in the year following the first MDA (1.48, 95% CI=1.23–
1.78, p,0.0001) and was dropped from final models of other years
Figure 3. Incidence of acute filariasis morbidity events in moderate and high transmission villages. The open circles represent data from
all 14 study villages combined. Villages are also stratified according to pre-MDA transmission intensity such that the down arrows represent moderate
transmission villages (pre-MDA values for 8 villages were 24–167 infective bites per person per year) and up arrows represent high transmission
villages (pre-MDA values for 6 villages were 224 to 742 infective bites per persons per year). High transmission villages experienced significantly
greater AFM incidence in each year of the study compared to moderate transmission villages (p,0.001).
doi:10.1371/journal.pntd.0001241.g003
Table 2. Acute filariasis morbidity incidence according to study year stratified by pre-treatment transmission intensity.
Study Year 1 Study Year 2 Study Year 3 Study Year 4 Study Year 5
Transmission Index of
Villages
Pre-treatment
Year
Year Following
1st MDA*
Year Following
2nd MDA
Year Following
3rd MDA
Year Following
4th MDA
Moderate-Transmission Population (n) 2,403 2,481 2,478 2,530 2,604
Person-years of
observation (pyo)
2,532 2,289 2,442 2,345 2,381
Total number of acute
events
711 587 298 354 385
Total number of leg
episodes
523 433 235 258 294
Events/pyo{ 0.28 0.26 0.12 0.15 0.16
Leg episodes/pyo 0.21 0.19 0.10 0.11 0.12
High-Transmission Population (n) 889 881 890 896 946
Person-years of
observation (pyo)
1,176 749 887 755 853
Total number of
acute events
731 357 216 247 259
Total number of
leg episodes
551 277 169 188 203
Events/pyo 0.62 0.48 0.24 0.33 0.30
Leg episodes/pyo 0.47 0.37 0.19 0.25 0.24
Moderate-transmission communities had infective biting rates of 24–167/person/year and high-transmission communities 224–742/person/year.
*MDA=mass drug administration;
{pyo=person-years of observation.
doi:10.1371/journal.pntd.0001241.t002
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MDA transmission potential and chronic LF pathology remained
significant positive predictors of AFM overall and during the pre-
MDA and after the fourth MDA year (p-values from 0.0452 to
,0.0001; Table S2). The pre-treatment risk of AFM due to the
independent effects of age $45 years (IRR=1.28, 95% CI=1.07–
1.53, p=0.0063), residence in a village with high pre-MDA
transmission intensity (IRR=2.56, 95% CI=2.19–3.00,
p,0.0001) and antigenemia (IRR=1.26, 95% CI=1.01–1.57,
p=0.0358) remained similar after four rounds of MDA, although
antigenemia did not achieve statistical significance after four
rounds of MDA (IRR=1.52, 95%CI=0.93–2.49, p=0.0933)
(Table S2). Though this study population experienced a decrease
in chronic lymphedema of the leg and hydrocele prevalence after
four MDAs [3], the risk of AFM associated with these two chronic
forms of clinical pathology increased from an IRR of 3.56 (95%
CI=3.02–4.19, p,0.0001) to 7.95 (95% CI=5.34–11.79,
p,0.0001) over the same period (p,0.0001). In other words,
among those individuals with pre-existing chronic lymphatic
pathology, AFM incidence increased from 1.81 per person-year
of observation (95% CI=1.66–1.98) in the pre-treatment year to
2.16 (95% CI=1.81–2.59) in the year following the fourth annual
MDA (p,0.0001). Conversely, AFM risk in individuals without
pre-existing chronic lymphatic disease decreased from 0.28 per
person-year of observation (95% CI=0.26–0.31) in the pre-
treatment year to 0.18 (95% CI=0.16–0.20) in the year following
the fourth annual MDA (p=0.17). This effect was significant
independently of village transmission despite the fact that the
overall prevalence of chronic disease was more common in high
versus moderate transmission villages (10.5% versus 3.4%,
p,0.001 pretreatment and 5.6% versus 2.5% following the fourth
MDA, p=0.025).
In order to evaluate whether the frequency of AFM events was
predictive of the development of chronic lymphatic pathology, we
compared AFM incidence among age-matched groups of
individuals who underwent two physical examinations during the
pre-treatment year, i.e. 12 months and 1–2 days before the first
MDA. Among those individuals who were newly diagnosed with
chronic lymphatic pathology during this one-year interval, the risk
of experiencing an AFM event at any anatomic site was 0.64 (95%
CI=0.59–0.68), whereas the risk among individuals who were
found not to develop chronic disease was 0.38 (95% CI=0.35–
0.42). For those individuals who had pre-existing chronic disease
(i.e., positive physical findings at 12 months and 1–2 days before
the first MDA) the risk was 2.38 (95% CI=2.14–2.63). Each of
these groups was significantly different from each other
(p,0.0001). The results were similar when the analysis was
restricted to leg events only. Taken together, these data suggest the
AFM events precede the development of chronic lymphatic
pathology and once established, chronic pathology further
increases the likelihood of repeated AFM events. We did not
perform a similar analysis for subsequent study years since the
overall incidence of AFM was reduced by MDA.
Discussion
We describe a comprehensive active surveillance of AFM events
during repeated MDAs in an area of Papua New Guinea where
LF is highly endemic. The incidence of AFM in this population
decreased to 57% of the pre-treatment level after 2 annual MDAs
in areas of moderate transmission and by 61% in areas of high
transmission. This rapid decrease in AFM incidence was sustained
over the entire 5-year surveillance period, thereby highlighting the
potential of MDA to alleviate this feature of LF morbidity. Of
concern, however, is the doubling of AFM events during the 4-
week period following the first MDA (Figures 1 and 2). This
transient increase was not, however, observed following subse-
quent MDAs. In fact, the multivariable models demonstrated that
microfilaremia predicted AFM incidence only during the year
following the first MDA, but not during the pre-treatment or any
other post-MDA year. Drug-induced adverse events have been
previously recorded following treatment with anti-filarial drugs,
particularly among individuals with high levels of microfilaremia
[30,31]. The significantly higher incidence of AFM events among
residents of communities with high versus moderate transmission
intensities (Table 2) is consistent with these observations. The
absence of periodic increases in AFM with subsequent treatments
indicates that the individual microfilarial densities may have
decreased sufficiently following the first annual MDA to eliminate
drug-induced AFM following subsequent MDAs. More generally,
these observations suggest that treatment naı ¨ve populations are
likely to be at increased risk of adverse events during the early
phase of MDA programs.
With regard to the study objectives, we have demonstrated a
significant decrease in AFM following mass administration of anti-
filarial drugs and the resulting decrease in indices of transmission
by the local mosquito vectors. Our results showed that the
incidence density of AFM remained stable following the first two
MDAs, though the rates remained twice that reported from other
LF endemic regions such as Tanzania [20], India [21] and Ghana
[22]. AFM events in the latter phases of our study (post MDA
years 3 and 4), when village-specific microfilaria levels and
mosquito transmission of infective larvae were reduced respec-
tively by 89–98% and 84–97% relative to the pre-MDA values
[24], may be attributed to active LF infections that were not cured
by earlier MDAs, pre-existing chronic LF pathology, and/or
continued exposure to infective larvae [9,10,12]. Alternatively, the
high rate of persisting AFM compared with other endemic regions
(where post-MDA AFM was not examined) may be due to
increased sensitivity of our follow-up protocols or low specificity of
the case definition. With respect to the latter consideration, we did
not attempt to determine whether self-reported fever accompanied
by painful swelling of an extremity was due to an injury that
promoted secondary bacterial infection of the arm or leg (shoes or
other footwear were not used by most study participants), and
malaria is highly endemic in this region of Papua New Guinea. We
believe that malaria is unlikely to be a cause of incorrect
categorization given that malaria-associated fevers in this region
occur primarily in children younger than 5 years [32], whereas
AFM occurs in adults. Regardless, the case definition used here is
comparable to that used in other settings where these and other
co-morbidities are present [11,20–22].
Our results strongly support the current global strategy to
eliminate LF through the use of repeated annual MDAs [33–38].
At the same time, the observations highlight important questions
pertaining to the pathogenesis of AFM. Currently, acute morbidity
events that involve painful swelling of the extremities, especially
the legs, are classified according to whether they are due to
secondary bacterial infection versus worm-associated etiologies
[9,10,12]. Our study design did not allow us to distinguish between
bacterial and filarial etiologies of AFM. To do so would require
clinical monitoring in the home, bacterial culture of affected
tissues, provision of antibiotics, and an estimate of adult worm
death (e.g. scrotal ultrasound) [8,9,11,39]. Biopsy of inflamed
tissue to assess adult worm viability or the presence of W. bancrofti
third or fourth-stage larvae is not justifiable clinically or ethically.
Unlike studies of secondary bacterial infections of the skin, which
to date have been limited to self-referred patients with pre-existing
Acute Filariasis Morbidity in Papua New Guinea
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population during repeated annual MDAs and noted that, though
AFM rates were significantly greater in participants with pre-
existing chronic LF pathology documented by physical examina-
tion, AFM rates also remained high for individuals with no pre-
existing chronic LF pathology (incidence 0.28 per person-year of
observation before MDA and 0.18 after four annual MDAs).
Thus, while secondary bacterial infections associated with chronic
lymphatic pathology of the leg may have played a role in the
pathogenesis of some cases of AFM observed here, inflammatory
reactions to adult worm or filarial larvae were also likely to have
contributed. Regardless, the 48% decrease in AFM events
following five rounds of MDA occurred in the absence of foot
hygiene or antibiotic interventions which have been shown in
other studies to independently decrease AFM events by 30 to 60%
[6,40]. This study supports current efforts to integrate hygiene and
MDA for LF elimination. Finally, cases occurring in individuals
without detectable LF infection presumably represent individuals
who experienced morbidity events that were truly unrelated to W.
bancrofti infection and/or have pre-patent LF infections that are
below the limits of detection with the assays used here. It is also
possible that some immune individuals have filarial antigen in their
tissues from previous, cured infection without detectable antigen-
emia at the time of sampling.
The data reported here suggest various ways that the current
strategy to eliminate LF may be modified from an operational
perspective. Given the dramatic rise in AFM events that occurred
immediately following the first MDA, community education
regarding this possibility of experiencing such events may be
important to sustain compliance over repeated annual MDAs,
especially in endemic regions where heavily infected individuals
and populations exist. Increased follow-up and case management
of AFM during the early phase of MDA implementation may also
be warranted. Finally, if indeed exposure to infective third stage or
subsequent larval stages that develop in the lymphatics of recently
re-infected or newly infected humans are involved in the
pathogenesis of AFM, intensified efforts to reduce mosquito
transmission such as by stepped-up vector control may be
warranted.
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